label: Delta-MRD400
label_lc: delta-mrd400
description: "An indication of a 400-fold reduction in measurable residual disease (MRD) correlated to the expression of clonal B-cell receptors (BCR) and T-cell receptors (TCR) in peripheral blood cell samples from subjects following treatment of a lymphoid malignancy as determined by the proprietary next generation sequencing-based clonoSEQ assay."